Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non Muscle Invasive Bladder Cancer pipeline constitutes 20+ key companies continuously working towards developing 22+ Non Muscle Invasive Bladder Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Non Muscle Invasive Bladder Cancer Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non Muscle Invasive Bladder Cancer Market.

The Pipeline report for Non-Muscle Invasive Bladder Cancer provides a thorough evaluation of commercial and clinical aspects of pipeline products, spanning from pre-clinical development to market availability. It includes an extensive overview of each drug, detailing its mechanism of action, clinical studies, potential NDA approvals, and various product development activities. These encompass technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details related to the product's development.

Get a Free Sample PDF Report to know more about Non Muscle Invasive Bladder Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight [https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key takeaways from the Non Muscle Invasive Bladder Cancer Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Non Muscle Invasive Bladder Cancer treatment therapies with a considerable amount of success over the years.

*
Non Muscle Invasive Bladder Cancer companies working in the treatment market are Tollys, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceuticals, and others, are developing therapies for the Non Muscle Invasive Bladder Cancer treatment

*
Emerging Non Muscle Invasive Bladder Cancer therapies in the different phases of clinical trials are- TL-532, AU-011, TARA-002, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, and others are expected to have a significant impact on the Non Muscle Invasive Bladder Cancer market in the coming years.

*
In March 2026, The FDA has approved an updated label for nadofaragene firadenovec-vncg (Adstiladrin), enabling more efficient clinical preparation for healthcare teams. According to a news release from Ferring Pharmaceuticals, the update introduces a faster 25-minute water-bath thawing method. Nadofaragene firadenovec was originally approved by the FDA in December 2022 for treating patients with high-risk BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

*
In March 2026, ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced that the U.S. Food and Drug Administration (FDA) has received its supplemental Biologics License Application (sBLA) for ANKTIVA Registered (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guerin (BCG). The application targets patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) presenting with papillary tumors.

*
bhas announced positive topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guerin (BCG) for patients with BCG-naive, high-risk non-muscle invasive bladder cancer (NMIBC). The study successfully met its primary endpoint of event-free survival (EFS), as assessed by investigators, showing a statistically significant and clinically meaningful improvement when sasanlimab was combined with BCG (both induction and maintenance) compared to BCG alone.

*
In January 2025, Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company specializing in next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TYRA-300. This approval allows the company to advance TYRA-300 into a Phase 2 clinical trial for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). The program will be led by Dr. Erik Goluboff, the newly appointed SVP of Clinical Development, who brings over 30 years of experience in urologic oncology and drug development.

*
In October 2024, Aura Biosciences, Inc. (NASDAQ: AURA) announced encouraging early results from its ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle invasive bladder cancer (NMIBC). The trial has enrolled 13 patients to date, with primary objectives focused on assessing the safety and feasibility of bel-sar administered locally, both as a standalone treatment (n=5) and with light activation (n=8). Secondary objectives include evaluating biological activity and immune-mediated changes within the tumor microenvironment (TME). Among the participants, 10 had low-grade disease, reflecting the approximately 70% prevalence of low-grade NMIBC in this patient population, while 3 had high-grade disease. In the group treated with bel-sar and light activation (n=8), 4 of 5 patients with low-grade disease achieved a clinical complete response, with no tumor cells detected upon histopathological evaluation. Additionally, 2 of 3 patients with high-grade disease showed visible tumor shrinkage on cystoscopy.

*
In October 2024, UroGen Pharma has announced the administration of the first dose in the Phase III UTOPIA clinical trial of its investigational drug, UGN-103 (mitomycin), an intravesical solution designed to treat low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial plans to enroll 87 participants and will evaluate the efficacy and safety of this potential treatment.

Non Muscle Invasive Bladder Cancer Overview

Non-Muscle Invasive Bladder Cancer (NMIBC) is a type of bladder cancer that remains confined to the inner lining of the bladder and has not spread to the muscle layer. It is the most common form of bladder cancer, typically diagnosed through urine tests, cystoscopy, and biopsy. NMIBC can be classified into low-grade or high-grade categories, with low-grade being less aggressive. While treatable, NMIBC requires ongoing monitoring due to its potential to recur or progress to muscle-invasive bladder cancer. Treatment often includes procedures like transurethral resection of the bladder tumor (TURBT) and intravesical therapies.

Stay ahead of emerging therapies and key developments in Non Muscle Invasive Bladder Cancer with comprehensive pipeline insights, trends, and market analysis, Non Muscle Invasive Bladder Cancer Clinical Trials Analysis [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Non Muscle Invasive Bladder Cancer Drugs Under Different Phases of Clinical Development Include:

*
TL-532: Tollys

*
AU-011: Aura Biosciences

*
TARA-002: Protara Therapeutics

*
VAX 014: Vaxiion Therapeutics

*
Pemigatinib: Incyte Corporation

*
Erdafitinib: Janssen Pharmaceuticals

*
TLD 1433: Theralase Technologies

*
PF-06801591: Pfizer

*
Nivolumab: BristolMyers Squibb

*
APL-1202: Asieris Pharmaceuticals

Non Muscle Invasive Bladder Cancer Route of Administration

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Non Muscle Invasive Bladder Cancer Molecule Type

Non Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

Non Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment

*
Non Muscle Invasive Bladder Cancer Assessment by Product Type

*
Non Muscle Invasive Bladder Cancer By Stage and Product Type

*
Non Muscle Invasive Bladder Cancer Assessment by Route of Administration

*
Non Muscle Invasive Bladder Cancer By Stage and Route of Administration

*
Non Muscle Invasive Bladder Cancer Assessment by Molecule Type

*
Non Muscle Invasive Bladder Cancer by Stage and Molecule Type

DelveInsight's Non Muscle Invasive Bladder Cancer Report covers around 25+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Non Muscle Invasive Bladder Cancer product details are provided in the report. Download the Non Muscle Invasive Bladder Cancer pipeline report to learn more about the emerging Non Muscle Invasive Bladder Cancer therapies [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Non Muscle Invasive Bladder Cancer Therapeutics Market include:

Key companies developing therapies for Non Muscle Invasive Bladder Cancer are - Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, Bristol-Myers Squibb, Asieris Pharmaceuticals, UroGen Pharma, CG Oncology, Sesen Bio, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Taizhou Hanzhong Biomedical, Spectrum Pharmaceuticals, FKD therapies, Altor Biosciences, Heat Biologics, EMD Sereno, QED Therapeutics, and others.

Non Muscle Invasive Bladder Cancer Pipeline Analysis:

The Non Muscle Invasive Bladder Cancer pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Non Muscle Invasive Bladder Cancer with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Muscle Invasive Bladder Cancer Treatment.

*
Non Muscle Invasive Bladder Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Non Muscle Invasive Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Muscle Invasive Bladder Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non Muscle Invasive Bladder Cancer drugs and therapies [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Non Muscle Invasive Bladder Cancer Pipeline Market Drivers

*
Increase in the number of patients suffering from non-muscle invasive bladder cancer. Approximately 70-75%bladder cancers are non-muscle invasive bladder cancer (NMIBC), development of novel therapies and favorable government policies are some of the important factors that are fueling the Non Muscle Invasive Bladder Cancer Market.

Non Muscle Invasive Bladder Cancer Pipeline Market Barriers

*
However, identifying the patient population with specific mutations for targeted therapy regimens, lack of awareness about the advanced cancer therapies and other factors are creating obstacles in the Non Muscle Invasive Bladder Cancer Market growth.

Scope of Non Muscle Invasive Bladder Cancer Pipeline Drug Insight

*
Coverage: Global

*
Key Non Muscle Invasive Bladder Cancer Companies: Tollys, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceuticals, and others

*
Key Non Muscle Invasive Bladder Cancer Therapies: TL-532, AU-011, TARA-002, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, and others

*
Non Muscle Invasive Bladder Cancer Therapeutic Assessment: Non Muscle Invasive Bladder Cancer current marketed and Non Muscle Invasive Bladder Cancer emerging therapies

*
Non Muscle Invasive Bladder Cancer Market Dynamics: Non Muscle Invasive Bladder Cancer market drivers and Non Muscle Invasive Bladder Cancer market barriers

Request for Sample PDF Report for Non Muscle Invasive Bladder Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Non Muscle Invasive Bladder Cancer Report Introduction

2. Non Muscle Invasive Bladder Cancer Executive Summary

3. Non Muscle Invasive Bladder Cancer Overview

4. Non Muscle Invasive Bladder Cancer- Analytical Perspective In-depth Commercial Assessment

5. Non Muscle Invasive Bladder Cancer Pipeline Therapeutics

6. Non Muscle Invasive Bladder Cancer Late Stage Products (Phase II/III)

7. Non Muscle Invasive Bladder Cancer Mid Stage Products (Phase II)

8. Non Muscle Invasive Bladder Cancer Early Stage Products (Phase I)

9. Non Muscle Invasive Bladder Cancer Preclinical Stage Products

10. Non Muscle Invasive Bladder Cancer Therapeutics Assessment

11. Non Muscle Invasive Bladder Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non Muscle Invasive Bladder Cancer Key Companies

14. Non Muscle Invasive Bladder Cancer Key Products

15. Non Muscle Invasive Bladder Cancer Unmet Needs

16 . Non Muscle Invasive Bladder Cancer Market Drivers and Barriers

17. Non Muscle Invasive Bladder Cancer Future Perspectives and Conclusion

18. Non Muscle Invasive Bladder Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=non-muscle-invasive-bladder-cancer-pipeline-2026-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-aura-biosciences-protara-therapeutics-vaxiion-therapeutics-incyte-corp]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.